Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9650-0.0450 (-4.46%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.0100
Open1.0200
Bid0.9469 x 2200
Ask1.0000 x 1300
Day's Range0.9202 - 1.0100
52 Week Range0.9000 - 16.9400
Volume390,736
Avg. Volume235,296
Market Cap87.431M
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.9010
Earnings DateAug 22, 2022 - Aug 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.76
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genetron Holdings Limited
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
    Rating
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
  • GlobeNewswire

    Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day

    BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day. Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan

  • GlobeNewswire

    Genetron Health Receives CAP Accreditation for its Maryland Laboratory

    BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced College of American Pathologists (CAP) Accreditation for its laboratory in Maryland, U.S. CAP Accreditation is designed to help laboratories maintain the accuracy of test results and

  • GlobeNewswire

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the f

Advertisement
Advertisement